Back to results
US 12,747,425 B2Granted
Ex vivo proliferation of epithelial cells
AssigneePropagenix Inc.
InventorChengkang Zhang
Life of this patent
Estimating the term…
Abstract
The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.
Claims19
A method for proliferating epithelial cells ex vivo, comprising:
- expanding the number of cells in an originating epithelial cell population under serum-free and feeder-cell free expansion culture conditions, thereby generating an expanded epithelial cell population, wherein the expansion culture conditions comprise inhibitors consisting of (i) one or more transforming growth factor beta (TGF-beta) inhibitors and (ii) one or more inhibitors selected from a Rho-associated protein kinase inhibitor, a p21-activated kinase (PAK) inhibitor, and a myosin II inhibitor.
A method for proliferating epithelial cells ex vivo, comprising:
- expanding the number of cells in an originating epithelial cell population isolated from tissue or a tissue biopsy from a subject under serum-free and feeder-cell free expansion culture conditions, thereby generating an expanded epithelial cell population, wherein the expansion culture conditions comprise:
- a) inhibitors consisting of (i) one or more inhibitors of ALK5, ALK4, and/or ALK7, and (ii) one or more inhibitors selected from a Rho-associated protein kinase inhibitor, a p21-activated kinase (PAK) inhibitor, and a myosin II inhibitor;
- b) a beta-adrenergic receptor agonist;
- c) one or more mitogenic growth factors;
- and
- d) calcium at a concentration below 100 μM.
3 more elements
A composition comprising:
- a) a serum-free and feeder cell-free base medium, and
- b) inhibitors consisting of (i) one or more transforming growth factor beta (TGF-beta) inhibitors and (ii) one or more inhibitors selected from a Rho-associated protein kinase inhibitor, a p21-activated kinase (PAK) inhibitor, and a myosin II inhibitor.
Dependencies are inferred from the claim text.